Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07115238) titled 'Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD' on Aug. 4.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Diagnostic. Masking: Single (Outcomes Assessor).
Primary Sponsor: Sinotau Pharmaceutical Group
Condition:
Alzheimer Disease
Neurofibrillary Tangle
Intervention:
Drug: XTR006
Recruitment Status: Recruiting
Phase: Phase 3
Date of First Enrollment: November 20, 2024
Target Sample Size: 354
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/ct2/sh...